GLOBUS MEDICAL INC - A (GMED) Fundamental Analysis & Valuation

NYSE:GMED • US3795772082

Current stock price

90.42 USD
-0.98 (-1.07%)
At close:
90.42 USD
0 (0%)
After Hours:

This GMED fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. GMED Profitability Analysis

1.1 Basic Checks

  • GMED had positive earnings in the past year.
  • In the past year GMED had a positive cash flow from operations.
  • GMED had positive earnings in each of the past 5 years.
  • GMED had a positive operating cash flow in each of the past 5 years.
GMED Yearly Net Income VS EBIT VS OCF VS FCFGMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • GMED has a Return On Assets of 10.14%. This is amongst the best in the industry. GMED outperforms 90.43% of its industry peers.
  • The Return On Equity of GMED (11.76%) is better than 85.11% of its industry peers.
  • GMED's Return On Invested Capital of 9.75% is amongst the best of the industry. GMED outperforms 88.83% of its industry peers.
  • GMED had an Average Return On Invested Capital over the past 3 years of 5.99%. This is below the industry average of 9.15%.
  • The last Return On Invested Capital (9.75%) for GMED is above the 3 year average (5.99%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.14%
ROE 11.76%
ROIC 9.75%
ROA(3y)4.84%
ROA(5y)6.26%
ROE(3y)5.77%
ROE(5y)7.23%
ROIC(3y)5.99%
ROIC(5y)7.61%
GMED Yearly ROA, ROE, ROICGMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 18.30%, GMED belongs to the best of the industry, outperforming 93.62% of the companies in the same industry.
  • In the last couple of years the Profit Margin of GMED has grown nicely.
  • GMED has a better Operating Margin (18.30%) than 89.36% of its industry peers.
  • GMED's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 67.41%, GMED is in the better half of the industry, outperforming 73.40% of the companies in the same industry.
  • In the last couple of years the Gross Margin of GMED has remained more or less at the same level.
Industry RankSector Rank
OM 18.3%
PM (TTM) 18.3%
GM 67.41%
OM growth 3Y-7.48%
OM growth 5Y4.58%
PM growth 3Y-0.53%
PM growth 5Y7.14%
GM growth 3Y-3.16%
GM growth 5Y-1.43%
GMED Yearly Profit, Operating, Gross MarginsGMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GMED Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so GMED is still creating some value.
  • GMED has less shares outstanding than it did 1 year ago.
  • GMED has more shares outstanding than it did 5 years ago.
  • GMED has a better debt/assets ratio than last year.
GMED Yearly Shares OutstandingGMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
GMED Yearly Total Debt VS Total AssetsGMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • GMED has an Altman-Z score of 11.68. This indicates that GMED is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of GMED (11.68) is better than 91.49% of its industry peers.
  • The Debt to FCF ratio of GMED is 0.00, which is an excellent value as it means it would take GMED, only 0.00 years of fcf income to pay off all of its debts.
  • GMED's Debt to FCF ratio of 0.00 is amongst the best of the industry. GMED outperforms 93.62% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that GMED is not too dependend on debt financing.
  • The Debt to Equity ratio of GMED (0.00) is better than 76.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.68
ROIC/WACC1.1
WACC8.87%
GMED Yearly LT Debt VS Equity VS FCFGMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 4.26 indicates that GMED has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.26, GMED is doing good in the industry, outperforming 67.02% of the companies in the same industry.
  • GMED has a Quick Ratio of 2.74. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 2.74, GMED is doing good in the industry, outperforming 60.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 2.74
GMED Yearly Current Assets VS Current LiabilitesGMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. GMED Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 27.39% over the past year.
  • GMED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.84% yearly.
  • Looking at the last year, GMED shows a quite strong growth in Revenue. The Revenue has grown by 16.65% in the last year.
  • The Revenue has been growing by 30.08% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)27.39%
EPS 3Y24.56%
EPS 5Y22.84%
EPS Q2Q%52.38%
Revenue 1Y (TTM)16.65%
Revenue growth 3Y42.17%
Revenue growth 5Y30.08%
Sales Q2Q%25.73%

3.2 Future

  • Based on estimates for the next years, GMED will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.57% on average per year.
  • Based on estimates for the next years, GMED will show a small growth in Revenue. The Revenue will grow by 7.38% on average per year.
EPS Next Y14%
EPS Next 2Y12.42%
EPS Next 3Y11.9%
EPS Next 5Y11.57%
Revenue Next Year9.89%
Revenue Next 2Y8.07%
Revenue Next 3Y7.79%
Revenue Next 5Y7.38%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GMED Yearly Revenue VS EstimatesGMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
GMED Yearly EPS VS EstimatesGMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. GMED Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 22.61 indicates a rather expensive valuation of GMED.
  • GMED's Price/Earnings ratio is a bit cheaper when compared to the industry. GMED is cheaper than 75.53% of the companies in the same industry.
  • GMED is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.86, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 19.83, which indicates a rather expensive current valuation of GMED.
  • 79.79% of the companies in the same industry are more expensive than GMED, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of GMED to the average of the S&P500 Index (37.39), we can say GMED is valued slightly cheaper.
Industry RankSector Rank
PE 22.61
Fwd PE 19.83
GMED Price Earnings VS Forward Price EarningsGMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GMED is valued cheaper than 80.32% of the companies in the same industry.
  • 87.23% of the companies in the same industry are more expensive than GMED, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.12
EV/EBITDA 14.29
GMED Per share dataGMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • GMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GMED may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)0.99
EPS Next 2Y12.42%
EPS Next 3Y11.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMED Dividend Analysis

5.1 Amount

  • GMED does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMED Fundamentals: All Metrics, Ratios and Statistics

GLOBUS MEDICAL INC - A

NYSE:GMED (4/10/2026, 8:27:42 PM)

After market: 90.42 0 (0%)

90.42

-0.98 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-01
Inst Owners101.87%
Inst Owner Change0.05%
Ins Owners0.68%
Ins Owner Change2.45%
Market Cap12.23B
Revenue(TTM)2.94B
Net Income(TTM)537.87M
Analysts78.18
Price Target108.12 (19.58%)
Short Float %2.95%
Short Ratio2.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.49%
Min EPS beat(2)9.18%
Max EPS beat(2)47.79%
EPS beat(4)3
Avg EPS beat(4)14.55%
Min EPS beat(4)-10.39%
Max EPS beat(4)47.79%
EPS beat(8)7
Avg EPS beat(8)15.89%
EPS beat(12)9
Avg EPS beat(12)10.63%
EPS beat(16)11
Avg EPS beat(16)7.24%
Revenue beat(2)2
Avg Revenue beat(2)2.03%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)2.67%
Revenue beat(8)6
Avg Revenue beat(8)-0.05%
Revenue beat(12)8
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)-0.79%
PT rev (1m)1.02%
PT rev (3m)10.03%
EPS NQ rev (1m)0.7%
EPS NQ rev (3m)3.21%
EPS NY rev (1m)0.9%
EPS NY rev (3m)8.44%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)1.54%
Revenue NY rev (1m)0.37%
Revenue NY rev (3m)2.67%
Valuation
Industry RankSector Rank
PE 22.61
Fwd PE 19.83
P/S 4.16
P/FCF 21.12
P/OCF 16.23
P/B 2.67
P/tB 5.11
EV/EBITDA 14.29
EPS(TTM)4
EY4.42%
EPS(NY)4.56
Fwd EY5.04%
FCF(TTM)4.28
FCFY4.73%
OCF(TTM)5.57
OCFY6.16%
SpS21.73
BVpS33.81
TBVpS17.69
PEG (NY)1.61
PEG (5Y)0.99
Graham Number55.17
Profitability
Industry RankSector Rank
ROA 10.14%
ROE 11.76%
ROCE 11.19%
ROIC 9.75%
ROICexc 11.03%
ROICexgc 22.66%
OM 18.3%
PM (TTM) 18.3%
GM 67.41%
FCFM 19.7%
ROA(3y)4.84%
ROA(5y)6.26%
ROE(3y)5.77%
ROE(5y)7.23%
ROIC(3y)5.99%
ROIC(5y)7.61%
ROICexc(3y)6.95%
ROICexc(5y)9.44%
ROICexgc(3y)15.9%
ROICexgc(5y)15.96%
ROCE(3y)6.88%
ROCE(5y)8.74%
ROICexgc growth 3Y10.02%
ROICexgc growth 5Y14.9%
ROICexc growth 3Y-7.63%
ROICexc growth 5Y4.43%
OM growth 3Y-7.48%
OM growth 5Y4.58%
PM growth 3Y-0.53%
PM growth 5Y7.14%
GM growth 3Y-3.16%
GM growth 5Y-1.43%
F-Score8
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 63.01%
Cap/Sales 5.93%
Interest Coverage 250
Cash Conversion 92.5%
Profit Quality 107.65%
Current Ratio 4.26
Quick Ratio 2.74
Altman-Z 11.68
F-Score8
WACC8.87%
ROIC/WACC1.1
Cap/Depr(3y)54.18%
Cap/Depr(5y)70.45%
Cap/Sales(3y)5.17%
Cap/Sales(5y)5.74%
Profit Quality(3y)211.86%
Profit Quality(5y)167.52%
High Growth Momentum
Growth
EPS 1Y (TTM)27.39%
EPS 3Y24.56%
EPS 5Y22.84%
EPS Q2Q%52.38%
EPS Next Y14%
EPS Next 2Y12.42%
EPS Next 3Y11.9%
EPS Next 5Y11.57%
Revenue 1Y (TTM)16.65%
Revenue growth 3Y42.17%
Revenue growth 5Y30.08%
Sales Q2Q%25.73%
Revenue Next Year9.89%
Revenue Next 2Y8.07%
Revenue Next 3Y7.79%
Revenue Next 5Y7.38%
EBIT growth 1Y63.49%
EBIT growth 3Y31.53%
EBIT growth 5Y36.04%
EBIT Next Year55.31%
EBIT Next 3Y22.54%
EBIT Next 5Y18.95%
FCF growth 1Y42.89%
FCF growth 3Y76.95%
FCF growth 5Y33.79%
OCF growth 1Y44.72%
OCF growth 3Y61.61%
OCF growth 5Y30.54%

GLOBUS MEDICAL INC - A / GMED Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GLOBUS MEDICAL INC - A (GMED) stock?

ChartMill assigns a fundamental rating of 7 / 10 to GMED.


What is the valuation status of GLOBUS MEDICAL INC - A (GMED) stock?

ChartMill assigns a valuation rating of 5 / 10 to GLOBUS MEDICAL INC - A (GMED). This can be considered as Fairly Valued.


What is the profitability of GMED stock?

GLOBUS MEDICAL INC - A (GMED) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for GMED stock?

The Price/Earnings (PE) ratio for GLOBUS MEDICAL INC - A (GMED) is 22.61 and the Price/Book (PB) ratio is 2.67.